TW497974B - High dose liposomal aerosol formulations - Google Patents

High dose liposomal aerosol formulations Download PDF

Info

Publication number: TW497974B
Authority: TW; Taiwan
Prior art keywords: cyclosporin; dlpc; liposome; concentration; aerosol
Prior art date: 1996-07-03

Application number

TW086101859A

Other languages

English (en)

Chinese (zh)

Inventor

J Clifford Waldrep

Vernon Knight

Melanie B Black

Original Assignee

Res Dev Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-03

Filing date

1997-02-17

Publication date

2002-08-11

1996-10-16 Priority claimed from US08/731,605 external-priority patent/US5958378A/en

1997-02-17 Application filed by Res Dev Foundation filed Critical Res Dev Foundation

2002-08-11 Application granted granted Critical

2002-08-11 Publication of TW497974B publication Critical patent/TW497974B/zh

Links

239000000443 aerosol Substances 0.000 title claims abstract description 113
239000000203 mixture Substances 0.000 title claims abstract description 91
238000009472 formulation Methods 0.000 title description 38
239000002502 liposome Substances 0.000 claims abstract description 128
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims abstract description 82
229930105110 Cyclosporin A Natural products 0.000 claims abstract description 81
108010036949 Cyclosporine Proteins 0.000 claims abstract description 81
229960001265 ciclosporin Drugs 0.000 claims abstract description 75
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 14
229960004436 budesonide Drugs 0.000 claims abstract description 14
FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 claims description 59
229930182912 cyclosporin Natural products 0.000 claims description 25
238000011049 filling Methods 0.000 claims description 24
239000002245 particle Substances 0.000 claims description 21
208000019693 Lung disease Diseases 0.000 claims description 14
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 12
229940067606 lecithin Drugs 0.000 claims description 12
239000000787 lecithin Substances 0.000 claims description 12
235000010445 lecithin Nutrition 0.000 claims description 12
239000003595 mist Substances 0.000 claims description 12
206010020751 Hypersensitivity Diseases 0.000 claims description 10
208000006673 asthma Diseases 0.000 claims description 10
208000026935 allergic disease Diseases 0.000 claims description 8
230000002757 inflammatory effect Effects 0.000 claims description 7
230000001404 mediated effect Effects 0.000 claims description 7
230000007815 allergy Effects 0.000 claims description 5
230000009610 hypersensitivity Effects 0.000 claims description 5
239000013598 vector Substances 0.000 claims description 5
206010061218 Inflammation Diseases 0.000 claims description 3
206010052779 Transplant rejections Diseases 0.000 claims description 3
206010006451 bronchitis Diseases 0.000 claims description 3
230000004054 inflammatory process Effects 0.000 claims description 3
239000000126 substance Substances 0.000 claims description 3
OQQOAWVKVDAJOI-UHFFFAOYSA-N (2-dodecanoyloxy-3-hydroxypropyl) dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCC OQQOAWVKVDAJOI-UHFFFAOYSA-N 0.000 claims description 2
210000003123 bronchiole Anatomy 0.000 claims description 2
235000017858 Laurus nobilis Nutrition 0.000 claims 1
244000147568 Laurus nobilis Species 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 28
150000003904 phospholipids Chemical class 0.000 abstract description 26
239000003862 glucocorticoid Substances 0.000 abstract description 12
230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
229940037128 systemic glucocorticoids Drugs 0.000 abstract description 7
230000001093 anti-cancer Effects 0.000 abstract description 4
230000003115 biocidal effect Effects 0.000 abstract description 4
230000001506 immunosuppresive effect Effects 0.000 abstract description 4
230000000840 anti-viral effect Effects 0.000 abstract description 3
230000000843 anti-fungal effect Effects 0.000 abstract 1
210000004072 lung Anatomy 0.000 description 31
239000003814 drug Substances 0.000 description 30
238000004458 analytical method Methods 0.000 description 29
229940079593 drug Drugs 0.000 description 29
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
239000007921 spray Substances 0.000 description 19
238000004128 high performance liquid chromatography Methods 0.000 description 14
230000002079 cooperative effect Effects 0.000 description 13
238000000034 method Methods 0.000 description 12
238000005507 spraying Methods 0.000 description 11
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
239000012071 phase Substances 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
239000002158 endotoxin Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000006199 nebulizer Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000008901 benefit Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
150000002632 lipids Chemical class 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000005259 measurement Methods 0.000 description 5
230000004044 response Effects 0.000 description 5
238000011282 treatment Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000000265 leukocyte Anatomy 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000003226 mitogen Substances 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
229910021642 ultra pure water Inorganic materials 0.000 description 4
239000012498 ultrapure water Substances 0.000 description 4
239000003643 water by type Substances 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000007726 management method Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000012452 mother liquor Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
210000004681 ovum Anatomy 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
238000005070 sampling Methods 0.000 description 3
238000004088 simulation Methods 0.000 description 3
230000007704 transition Effects 0.000 description 3
JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 2
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000003242 anti bacterial agent Chemical class 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
238000003491 array Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229940099578 hydrogenated soybean lecithin Drugs 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
-1 lauryl phospholipids Chemical class 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
210000001370 mediastinum Anatomy 0.000 description 2
238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
239000008389 polyethoxylated castor oil Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000013341 scale-up Methods 0.000 description 2
238000007789 sealing Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000004704 ultra performance liquid chromatography Methods 0.000 description 2
KILNVBDSWZSGLL-UHFFFAOYSA-O 2-[2,3-di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-UHFFFAOYSA-O 0.000 description 1
HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
241000238876 Acari Species 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
206010013952 Dysphonia Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
240000008415 Lactuca sativa Species 0.000 description 1
235000003228 Lactuca sativa Nutrition 0.000 description 1
206010051604 Lung transplant rejection Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102000003896 Myeloperoxidases Human genes 0.000 description 1
108090000235 Myeloperoxidases Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
NRRIAWBEPOWFOG-UHFFFAOYSA-N Ovalin Natural products CN1CCC(O)CC1C(O)=O NRRIAWBEPOWFOG-UHFFFAOYSA-N 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
238000001919 Rayleigh scattering spectroscopy Methods 0.000 description 1
244000020191 Salix babylonica Species 0.000 description 1
101000921780 Solanum tuberosum Cysteine synthase Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
229940037003 alum Drugs 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
210000001132 alveolar macrophage Anatomy 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
230000035565 breathing frequency Effects 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
230000035568 catharsis Effects 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229910003460 diamond Inorganic materials 0.000 description 1
239000010432 diamond Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
210000002468 fat body Anatomy 0.000 description 1
239000011152 fibreglass Substances 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
229940040145 liniment Drugs 0.000 description 1
239000000865 liniment Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000006140 methanolysis reaction Methods 0.000 description 1
RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
229960002455 methoxyflurane Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000010363 phase shift Effects 0.000 description 1
238000013031 physical testing Methods 0.000 description 1
HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical group [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
150000004671 saturated fatty acids Chemical group 0.000 description 1
238000000790 scattering method Methods 0.000 description 1
235000015170 shellfish Nutrition 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
235000012976 tarts Nutrition 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940098465 tincture Drugs 0.000 description 1
238000003325 tomography Methods 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
IMRYETFJNLKUHK-UHFFFAOYSA-N traseolide Chemical compound CC1=C(C(C)=O)C=C2C(C(C)C)C(C)C(C)(C)C2=C1 IMRYETFJNLKUHK-UHFFFAOYSA-N 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000007966 viscous suspension Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000008832 zhongfu Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Otolaryngology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TW086101859A 1996-07-03 1997-02-17 High dose liposomal aerosol formulations TW497974B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US67565496A	1996-07-03	1996-07-03
US08/731,605 US5958378A (en)	1996-07-03	1996-10-16	High dose liposomal aerosol formulations containing cyclosporin A or budesonide

Publications (1)

Publication Number	Publication Date
TW497974B true TW497974B (en)	2002-08-11

Family

ID=27101390

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW086101859A TW497974B (en)	1996-07-03	1997-02-17	High dose liposomal aerosol formulations

Country Status (10)

Country	Link
EP (1)	EP0959874B1 (2)
JP (1)	JP2001524930A (2)
CN (1)	CN1094345C (2)
AT (2)	ATE268163T1 (2)
AU (1)	AU732124B2 (2)
CA (1)	CA2259185C (2)
DE (2)	DE69736083T2 (2)
NZ (1)	NZ333497A (2)
TW (1)	TW497974B (2)
WO (1)	WO1998000111A1 (2)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6417172B1 (en) *	1995-06-05	2002-07-09	Eisai Co., Ltd.	Prevention and treatment of pulmonary bacterial infection or symptomatic pulmonary exposure to endotoxin by inhalation of antiendotoxin drugs
US5863910A (en) *	1996-01-12	1999-01-26	Bolonick; Joel	Treatment of chronic inflammatory disorders of the gastrointestinal tract
US6090407A (en)	1997-09-23	2000-07-18	Research Development Foundation	Small particle liposome aerosols for delivery of anti-cancer drugs
US7348025B2 (en)	1997-09-23	2008-03-25	Research Development Foundation	Small particle liposome aerosols for delivery of anticancer drugs
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en)	1997-09-29	2005-09-20	Nektar Therapeutics	Stabilized preparations for use in nebulizers
US6433040B1 (en)	1997-09-29	2002-08-13	Inhale Therapeutic Systems, Inc.	Stabilized bioactive preparations and methods of use
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US20020006901A1 (en)	1999-02-05	2002-01-17	Aldo T. Iacono	Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
JP2003501376A (ja) *	1999-06-04	2003-01-14	スカイファーマインコーポレーテッド	疎水性薬物の持続性放出のための油コア組成物
KR100799089B1 (ko) *	1999-12-04	2008-01-29	리서치 디벨럽먼트 파운데이션	에어로졸화된 약물의 침착 증진 조성물
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ES2525087T5 (es)	2000-05-10	2018-06-28	Novartis Ag	Polvos basados en fosfolípidos para administración de fármacos
JP2005514393A (ja)	2001-12-19	2005-05-19	ネクターセラピューティクス	アミノグリコシドの肺への供給
AU2003237863A1 (en) *	2002-05-20	2003-12-12	Research Development Foundation	Aerosol drug inhibition of lung metastases
US20050255154A1 (en)	2004-05-11	2005-11-17	Lena Pereswetoff-Morath	Method and composition for treating rhinitis
ES2462541T3 (es)	2005-06-09	2014-05-23	Meda Ab	Método y composición para el tratamiento de trastornos inflamatorios
DE102006051512A1 (de) *	2005-12-06	2007-06-14	Pari GmbH Spezialisten für effektive Inhalation	Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
CN101502484B (zh) *	2006-12-26	2011-04-20	济南康泉医药科技有限公司	同载糖皮质激素和化疗药物的抗癌缓释剂
WO2009062193A2 (en) *	2007-11-09	2009-05-14	Map Pharmaceuticals, Inc.	Methods for administering corticosteroid formulations
CN105168135A (zh)	2010-03-12	2015-12-23	博格有限责任公司	辅酶Q10(CoQ10)的静脉内制剂及其使用方法
EP2598128B1 (en)	2010-07-28	2018-03-28	Life Technologies Corporation	Anti- viral azide-containing compounds
US20120028335A1 (en)	2010-07-28	2012-02-02	Life Technologies Corporation	Anti-viral azide-containing compounds
CN103442694B (zh) *	2010-08-05	2015-09-09	皮拉马尔企业有限公司	治疗感染性疾病的肺部给药的抗感染分子微粒制剂
CN102008713B (zh) *	2010-12-02	2012-10-24	深圳海王药业有限公司	环孢素a前体脂质体、药物组合物及其制备方法
US10973763B2 (en) *	2011-06-17	2021-04-13	Berg Llc	Inhalable pharmaceutical compositions
GB201114332D0 (en)	2011-08-19	2011-10-05	Nufarm Uk Ltd	Novel inhibitor compositions and methods of use
SG11201404361UA (en)	2012-01-26	2014-09-26	Life Technologies Corp	Methods for increasing the infectivity of viruses
CA3104443A1 (en)	2018-06-27	2020-01-02	Breath Therapeutics Gmbh	Inhalable compositions comprising macrocyclic immunosuppressants
IL279760B2 (en) *	2018-06-27	2025-10-01	Breath Therapeutics Gmbh	Pharmaceutical preparations in lyophilized form
EA202092892A1 (ru) *	2018-12-04	2021-05-27	Брес Терапьютикс Гмбх	Ингаляционные композиции, содержащие макроциклические иммуносупрессанты

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8403905D0 (sv) *	1984-07-30	1984-07-30	Draco Ab	Liposomes and steroid esters
SE8603812D0 (sv) *	1986-09-12	1986-09-12	Draco Ab	Administration of liposomes to mammals
IE63869B1 (en) *	1986-11-06	1995-06-14	Res Dev Foundation	Aerosols containing liposomes and method for their preparation
US5049388A (en) *	1986-11-06	1991-09-17	Research Development Foundation	Small particle aerosol liposome and liposome-drug combinations for medical use
US4906476A (en) *	1988-12-14	1990-03-06	Liposome Technology, Inc.	Novel liposome composition for sustained release of steroidal drugs in lungs
MX9201782A (es) *	1991-04-19	1992-10-01	Sandoz Ag	Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
DE4203306A1 (de) *	1992-02-06	1993-08-12	Ig Spruehtechnik Gmbh	Asthma oder pulmonal-aerosolzubereitungen mit lecithin
AR002009A1 (es) *	1994-12-22	1998-01-07	Astra Ab	Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.

1997
- 1997-02-17 TW TW086101859A patent/TW497974B/zh not_active IP Right Cessation
- 1997-07-02 CA CA002259185A patent/CA2259185C/en not_active Expired - Fee Related
- 1997-07-02 WO PCT/US1997/011696 patent/WO1998000111A1/en not_active Ceased
- 1997-07-02 AU AU36508/97A patent/AU732124B2/en not_active Ceased
- 1997-07-02 DE DE69736083T patent/DE69736083T2/de not_active Expired - Lifetime
- 1997-07-02 DE DE69729391T patent/DE69729391T2/de not_active Expired - Lifetime
- 1997-07-02 AT AT97933287T patent/ATE268163T1/de not_active IP Right Cessation
- 1997-07-02 AT AT04009645T patent/ATE328583T1/de not_active IP Right Cessation
- 1997-07-02 CN CN97196141A patent/CN1094345C/zh not_active Expired - Fee Related
- 1997-07-02 NZ NZ333497A patent/NZ333497A/en not_active IP Right Cessation
- 1997-07-02 EP EP97933287A patent/EP0959874B1/en not_active Expired - Lifetime
- 1997-07-02 JP JP50449998A patent/JP2001524930A/ja active Pending

Also Published As

Publication number	Publication date
CA2259185C (en)	2009-12-15
ATE268163T1 (de)	2004-06-15
DE69736083T2 (de)	2006-12-28
DE69729391T2 (de)	2005-06-02
AU732124B2 (en)	2001-04-12
CN1094345C (zh)	2002-11-20
AU3650897A (en)	1998-01-21
NZ333497A (en)	2000-06-23
CN1224347A (zh)	1999-07-28
ATE328583T1 (de)	2006-06-15
EP0959874B1 (en)	2004-06-02
EP0959874A1 (en)	1999-12-01
DE69736083D1 (de)	2006-07-20
WO1998000111A1 (en)	1998-01-08
DE69729391D1 (de)	2004-07-08
JP2001524930A (ja)	2001-12-04
CA2259185A1 (en)	1998-01-08
EP0959874A4 (2)	1999-12-22

Legal Events

Date	Code	Title	Description
2003-01-29	GD4A	Issue of patent certificate for granted invention patent
2013-05-11	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
TW497974B (en)	2002-08-11	High dose liposomal aerosol formulations
US5958378A (en)	1999-09-28	High dose liposomal aerosol formulations containing cyclosporin A or budesonide
JP7430766B2 (ja)	2024-02-13	プロスタサイクリン化合物、組成物およびその使用方法
CA2372231C (en)	2009-09-01	Aerosol formulations and devices for increasing libido in women via acute testosterone administration
US5993781A (en)	1999-11-30	Fluticasone propionate nebulizable formulations
JP3818852B2 (ja)	2006-09-06	肺への薬物送達
EP1968538B1 (de)	2012-04-25	Pharmazeutische zusammensetzungen mit cyclosporin
US8367734B1 (en)	2013-02-05	Stable epinephrine suspension formulation with high inhalation delivery efficiency
SE459471B (sv)	1989-07-10	Liposomal aerosolkomposition samt foerfarande och foerpackning foer framstaellning daerav
WO2012047674A2 (en)	2012-04-12	Methods and compositions for disease treatment using inhalation
RU2012101619A (ru)	2013-07-27	Безопасное применение десмопрессина
HRP20221529T1 (hr)	2023-02-17	Sastavi za inhalaciju za upotrebu u liječenju plućnih bolesti
Morén et al.	1980	Fraction of dose exhaled after administration of pressurized inhalation aerosols
JPS61200849A (ja)	1986-09-05	リポソームの製造方法
Waldrep et al.	1997	High dose cyclosporin A and budesonide-liposome aerosols.
US11365248B2 (en)	2022-06-21	Formulation of tocilizumab and method for treating COVID-19 by inhalation
Safatov et al.	2005	A prototype prophylactic anti-influenza preparation in aerosol form on the basis of Abies sibirica polyprenols
RU2174390C2 (ru)	2001-10-10	Высокодозированные липосомные аэрозольные фармацевтические композиции
KR100497564B1 (ko)	2005-11-28	고용량의리포좀에어로졸제제
CN115835885B (zh)	2025-02-07	包含奥达特罗和布地奈德的药物组合物的制备
JP3202705B2 (ja)	2001-08-27	医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子
Khale et al.	2011	Liposomal Nebulising Solutions of Salbutamol Sulphate-A Characterisation Study
JP3202704B2 (ja)	2001-08-27	医療用のリポソームおよび薬物含有リポソームのエアゾールの小粒子
CN114712336A (zh)	2022-07-08	一种用于肺部给药的水性气溶胶、制备方法和用途
Akhuemokhan	0	Next Generation Nebuliser Formulations Background